Honda M, Wong SL, Healy MA, Nakajima T, Watanabe M, Fukuma S, et al. Long-term trends in primary sites of gastric adenocarcinoma in Japan and the United States. J Cancer. 2017;8(11):1935–42.

Article  PubMed  PubMed Central  Google Scholar 

Wani S, Holmberg D, Santoni G, Kauppila JH, Farkkila M, von Euler-Chelpin M, et al. Magnitude and time-trends of post-endoscopy esophageal adenocarcinoma and post-endoscopy esophageal neoplasia in a population-based cohort study: the Nordic Barrett’s Esophagus study. Gastroenterology. 2023;165(4):909-919.e13.

Article  PubMed  Google Scholar 

Matsuno K, Ishihara R, Ohmori M, Iwagami H, Shichijyo S, Maekawa A, et al. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. J Gastroenterol. 2019;54(9):784–91.

Article  CAS  PubMed  Google Scholar 

Urabe M, Ushiku T, Shinozaki-Ushiku A, Iwasaki A, Yamazawa S, Yamashita H, et al. Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: a comparative analysis according to Siewert classification in a Japanese cohort. Cancer Med. 2018;7(10):5145–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamada T, Kurose H, Yamanaka Y, Manabe N, Kusunoki H, Shiotani A, et al. Relationship between gastroesophageal junction adenocarcinoma and helicobacter pylori infection in Japan. Digestion. 2012;85(4):256–60.

Article  PubMed  Google Scholar 

Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.

Article  Google Scholar 

Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–74.

Article  CAS  Google Scholar 

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.

Article  CAS  PubMed  Google Scholar 

Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–7.

Article  CAS  PubMed  Google Scholar 

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshida T, Ogura G, Tanabe M, Hayashi T, Ohbayashi C, Azuma M, et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol Ther. 2022;23(1):191–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–68.

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–41.

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430–40.

Article  CAS  PubMed  Google Scholar 

Doki Y, Tanaka K, Kawachi H, Shirakawa Y, Kitagawa Y, Toh Y, et al. Japanese classification of Esophageal cancer, 12th Edition: Part II. Esophagus. 2024;21:216–69.

Article  PubMed  PubMed Central  Google Scholar 

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(4):446–64.

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

Article  CAS  PubMed  Google Scholar 

Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064–74.

Article  PubMed  PubMed Central  Google Scholar 

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–95.

Article  CAS  PubMed  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moehler M, Dvorkin M, Boku N, Özgüroǧlu M, Ryu MH, Muntean AS, et al. Phase III Trial of Avelumab Maintenance after First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients with Gastric Cancers: Results from JAVELIN Gastric 100. J Clin Oncol. 2021;39(9):966–77.

Article  CAS  PubMed  Google Scholar 

Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, et al. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol. 2016;40(11):1496–506.

Article  PubMed  Google Scholar 

Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol an Off J United States Can Acad Pathol Inc. 2017 Mar;30(3):427–39.

Attia S, El Hafez AA, Abdel-Aziz A, Elmetwaly S, Mokhtar N. Prognostic Value of PD-L1 Immunohistochemical Marker in Gastric Carcinoma and Its Correlation with HER2 Status. Asian Pacific J Cancer Prev. 2022;23(4):1433–44.

Article  CAS  Google Scholar 

Sughayer MA, Dabbagh TZ, Battah AH. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma. Appl Immunohistochem Mol Morphol. 2020;28(10):748–54.

Article  CAS  PubMed  Google Scholar 

Pereira MA, Ramos MFKP, Dias AR, Ribeiro R, Cardili L, Zilberstein B, et al. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Arch. 2021;478(6):1039–48.

Article  CAS  PubMed  Google Scholar 

Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23(1):95–104.

Article  CAS  PubMed  Google Scholar 

Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407–15.

Article  CAS  PubMed  Google Scholar 

Nakayama I, Takahari D, Chin K, Wakatsuki T, Takamatsu M, Yamamoto N, et al. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.